0 16 Characterization characterization NN 17 19 of of IN 20 21 5 5 CD 21 22 ’ ' SYM 23 26 end end NN 27 29 of of IN 30 35 human human JJ 36 47 thromboxane thromboxane NN 48 56 receptor receptor NN 57 61 gene gene NN 61 62 . . . 63 77 Organizational organizational JJ 78 86 analysis analysis NN 87 90 and and CC 91 98 mapping mapping NN 99 101 of of IN 102 109 protein protein NN 110 116 kinase kinase NNP 117 130 C–responsive c–responsive JJ 131 139 elements element NNS 140 150 regulating regulate VBG 151 161 expression expression NN 162 164 in in IN 165 174 platelets platelet NNS 174 175 . . . 177 185 Platelet Platelet NNP 186 197 thromboxane thromboxane NN 198 207 receptors receptor NNS 208 211 are be VBP 212 219 acutely acutely RB 220 223 and and CC 224 234 reversibly reversibly RB 235 246 upregulated upregulate VBN 247 252 after after IN 253 258 acute acute JJ 259 269 myocardial myocardial JJ 270 280 infarction infarction NN 280 281 . . . 282 284 To to TO 285 294 determine determine VB 295 297 if if IN 298 306 platelet platelet NN 307 318 thromboxane thromboxane NN 319 328 receptors receptor NNS 329 332 are be VBP 333 338 under under IN 339 354 transcriptional transcriptional JJ 355 362 control control NN 362 363 , , , 364 366 we we PRP 367 375 isolated isolate VBD 376 379 and and CC 380 393 characterized characterize VBD 394 399 human human JJ 400 407 genomic genomic JJ 408 411 DNA dna NN 412 418 clones clone NNS 419 429 containing contain VBG 430 433 the the DT 434 435 5 5 CD 435 436 ’ ' SYM 437 445 flanking flanking NN 446 452 region region NN 453 455 of of IN 456 459 the the DT 460 471 thromboxane thromboxane NN 472 480 receptor receptor NN 481 485 gene gene NN 485 486 . . . 487 490 The the DT 491 502 exon-intron exon-intron NN 503 512 structure structure NN 513 515 of of IN 516 519 the the DT 520 521 5 5 CD 521 522 ’ ' SYM 523 530 portion portion NN 531 533 of of IN 534 537 the the DT 538 549 thromboxane thromboxane NN 550 558 receptor receptor NN 559 563 gene gene NN 564 567 was be VBD 568 578 determined determine VBN 579 588 initially initially RB 589 591 by by IN 592 601 comparing compare VBG 602 605 the the DT 606 616 nucleotide nucleotide NN 617 625 sequence sequence NN 626 628 of of IN 629 632 the the DT 633 634 5 5 CD 634 635 ’ ' SYM 636 644 flanking flank VBG 645 652 genomic genomic JJ 653 658 clone clone NN 659 663 with with IN 664 668 that that DT 669 671 of of IN 672 673 a a DT 674 679 novel novel JJ 680 685 human human JJ 686 693 uterine uterine JJ 694 705 thromboxane thromboxane NN 706 714 receptor receptor NN 715 719 cDNA cdna NN 720 724 that that WDT 725 733 extended extend VBD 734 737 the the DT 738 742 mRNA mrna NN 743 746 141 141 CD 747 749 bp bp NN 750 757 further further RB 758 766 upstream upstream RB 767 771 than than IN 772 775 the the DT 776 786 previously previously RB 787 797 identified identify VBN 798 803 human human JJ 804 813 placental placental JJ 814 818 cDNA cdna NN 818 819 . . . 820 821 A a DT 822 827 major major JJ 828 841 transcription transcription NN 842 852 initiation initiation NN 853 857 site site NN 858 861 was be VBD 862 869 located locate VBN 870 872 in in IN 873 878 three three CD 879 884 human human JJ 885 892 tissues tissue NNS 893 906 approximately approximately RB 907 910 560 560 CD 911 913 bp bp NN 914 922 upstream upstream RB 923 927 from from IN 928 931 the the DT 932 943 translation translation NN 944 954 initiation initiation NN 955 960 codon codon NN 961 964 and and CC 965 968 380 380 CD 969 971 bp bp NN 972 980 upstream upstream RB 981 985 from from IN 986 989 any any DT 990 1000 previously previously RB 1001 1011 identified identify VBN 1012 1025 transcription transcription NN 1026 1036 initiation initiation NN 1037 1041 site site NN 1041 1042 . . . 1043 1046 The the DT 1047 1058 thromboxane thromboxane NN 1059 1067 receptor receptor NN 1068 1072 gene gene NN 1073 1076 has have VBZ 1077 1084 neither neither CC 1085 1086 a a DT 1087 1091 TATA TATA NNP 1092 1095 nor nor CC 1096 1097 a a DT 1098 1102 CAAT CAAT NNP 1103 1112 consensus consensus NN 1113 1117 site site NN 1117 1118 . . . 1119 1127 Promoter promoter NN 1128 1136 function function NN 1137 1139 of of IN 1140 1143 the the DT 1144 1145 5 5 CD 1145 1146 ’ ' SYM 1147 1155 flanking flanking NN 1156 1162 region region NN 1163 1165 of of IN 1166 1169 the the DT 1170 1181 thromboxane thromboxane NN 1182 1190 receptor receptor NN 1191 1195 gene gene NN 1196 1199 was be VBD 1200 1209 evaluated evaluate VBN 1210 1212 by by IN 1213 1225 transfection transfection NN 1226 1228 of of IN 1229 1240 thromboxane thromboxane NN 1241 1249 receptor receptor NN 1250 1254 gene gene NN 1255 1279 promoter/chloramphenicol promoter/chloramphenicol NN 1280 1297 acetyltransferase acetyltransferase NN 1298 1299 ( ( ( 1299 1302 CAT CAT NNP 1302 1303 ) ) ) 1304 1311 chimera chimera NN 1312 1320 plasmids plasmid NNS 1321 1325 into into IN 1326 1339 platelet-like platelet-like JJ 1340 1344 K562 k562 NN 1345 1350 cells cell NNS 1350 1351 . . . 1352 1363 Thromboxane Thromboxane NNP 1364 1372 receptor receptor NN 1373 1381 promoter promoter NN 1382 1390 activity activity NN 1390 1391 , , , 1392 1394 as as IN 1395 1403 assessed assess VBN 1404 1406 by by IN 1407 1410 CAT CAT NNP 1411 1421 expression expression NN 1421 1422 , , , 1423 1426 was be VBD 1427 1437 relatively relatively RB 1438 1442 weak weak JJ 1443 1446 but but CC 1447 1450 was be VBD 1451 1464 significantly significantly RB 1465 1473 enhanced enhance VBN 1474 1476 by by IN 1477 1484 phorbol phorbol NN 1485 1490 ester ester NN 1491 1500 treatment treatment NN 1500 1501 . . . 1502 1512 Functional functional JJ 1513 1521 analysis analysis NN 1522 1524 of of IN 1525 1526 5 5 CD 1526 1527 ’ ' SYM 1528 1536 deletion deletion NN 1537 1547 constructs construct NNS 1548 1550 in in IN 1551 1562 transfected transfecte VBN 1563 1567 K562 k562 NN 1568 1573 cells cell NNS 1574 1577 and and CC 1578 1581 gel gel NN 1582 1590 mobility mobility NN 1591 1596 shift shift NN 1597 1606 localized localize VBD 1607 1610 the the DT 1611 1616 major major JJ 1617 1624 phorbol phorbol NN 1625 1641 ester-responsive ester-responsive JJ 1642 1648 motifs motif NNS 1649 1651 in in IN 1652 1655 the the DT 1656 1667 thromboxane thromboxane NN 1668 1676 receptor receptor NN 1677 1681 gene gene NN 1682 1690 promoter promoter NN 1691 1693 to to TO 1694 1695 a a DT 1696 1703 cluster cluster NN 1704 1706 of of IN 1707 1716 activator activator NN 1717 1726 protein-2 protein-2 NN 1727 1728 ( ( ( 1728 1732 AP-2 ap-2 NN 1732 1733 ) ) ) 1734 1741 binding binding NN 1742 1751 consensus consensus NN 1752 1757 sites site NNS 1758 1765 located located JJ 1766 1779 approximately approximately RB 1780 1783 1.8 1.8 CD 1784 1786 kb kb NN 1787 1788 5 5 CD 1788 1789 ’ ' SYM 1790 1794 from from IN 1795 1798 the the DT 1799 1812 transcription transcription NN 1813 1823 initiation initiation NN 1824 1828 site site NN 1828 1829 . . . 1830 1835 These these DT 1836 1843 studies study NNS 1844 1847 are be VBP 1848 1851 the the DT 1852 1857 first first JJ 1858 1860 to to TO 1861 1870 determine determine VB 1871 1874 the the DT 1875 1884 structure structure NN 1885 1888 and and CC 1889 1901 organization organization NN 1902 1904 of of IN 1905 1908 the the DT 1909 1910 5 5 CD 1910 1911 ’ ' SYM 1912 1915 end end NN 1916 1918 of of IN 1919 1922 the the DT 1923 1934 thromboxane thromboxane NN 1935 1943 receptor receptor NN 1944 1948 gene gene NN 1949 1952 and and CC 1953 1964 demonstrate demonstrate VBP 1965 1969 that that IN 1970 1981 thromboxane thromboxane NN 1982 1990 receptor receptor NN 1991 1995 gene gene NN 1996 2006 expression expression NN 2007 2010 can can MD 2011 2013 be be VB 2014 2023 regulated regulate VBN 2024 2026 by by IN 2027 2037 activation activation NN 2038 2040 of of IN 2041 2048 protein protein NN 2049 2055 kinase kinase NNP 2056 2057 C C NNP 2058 2061 via via IN 2062 2071 induction induction NN 2072 2074 of of IN 2075 2077 an an DT 2078 2087 AP-2-like ap-2-like JJ 2088 2095 nuclear nuclear JJ 2096 2102 factor factor NN 2103 2110 binding bind VBG 2111 2113 to to TO 2114 2122 upstream upstream JJ 2123 2131 promoter promoter NN 2132 2140 elements element NNS 2140 2141 . . . 2142 2147 These these DT 2148 2156 findings finding NNS 2157 2165 strongly strongly RB 2166 2173 suggest suggest VBP 2174 2178 that that IN 2179 2182 the the DT 2183 2192 mechanism mechanism NN 2193 2196 for for IN 2197 2207 previously previously RB 2208 2217 described describe VBN 2218 2230 upregulation upregulation NN 2231 2233 of of IN 2234 2242 platelet platelet NN 2243 2254 thromboxane thromboxane NN 2255 2264 receptors receptor NNS 2265 2270 after after IN 2271 2276 acute acute JJ 2277 2287 myocardial myocardial JJ 2288 2298 infarction infarction NN 2299 2301 is be VBZ 2302 2311 increased increase VBN 2312 2323 thromboxane thromboxane NN 2324 2332 receptor receptor NN 2333 2337 gene gene NN 2338 2351 transcription transcription NN 2352 2354 in in IN 2355 2374 platelet-progenitor platelet-progenitor NN 2375 2380 cells cell NNS 2380 2381 . . .